(Q30573204)

English

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

0 references

author name string

Michele Kohli

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Donna Lawrence

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Jennifer Haig

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Andrea Anonychuk

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Nadia Demarteau

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

13 October 2012

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

BMC Public Health

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

872

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

13 October 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Financing Vaccines in the 21st Century: Assuring Access and Availability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Genital warts and cost of care in England

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Impact of HPV vaccination on young women's quality of life - a five year follow-up study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Budget impact analysis: review of the state of the art.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Anti-HPV vaccination: a review of recent economic data for Italy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

A review of human carcinogens--Part B: biological agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Infection and cervical neoplasia: facts and fiction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Economic evaluation of human papillomavirus vaccination in the United Kingdom

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Parental intention to have daughters receive the human papillomavirus vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Global cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Incidence, clearance and predictors of human papillomavirus infection in women.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Effectiveness and cost comparison of two strategies for hepatitis B vaccination of schoolchildren.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Cost-effectiveness of a potential vaccine for human papillomavirus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Meta-analysis of Pap test accuracy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

20 June 2018

Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

Epidemiology and costs associated with genital warts in Canada

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV).

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

The impact of anogenital warts on health-related quality of life: a 6-month prospective study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

[Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity

1 reference

https://api.crossref.org/works/10.1186%2F1471-2458-12-872

21 January 2018

Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

26 November 2018

Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

26 November 2018

Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503751

26 November 2018

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/23061913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toward consistency in cost-utility analyses: using national measures to create condition-specific values

1 reference

https://pubmed.ncbi.nlm.nih.gov/23061913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23061913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme

1 reference

https://pubmed.ncbi.nlm.nih.gov/23061913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2458-12-872

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30573204&oldid=2194939655"